{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T12:46:58Z","timestamp":1790858818875,"version":"4.1.0"},"reference-count":101,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":203,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Alzheimer's Disease"],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:p>Alzheimer\u2019s disease (AD) is a progressive neurodegenerative disorder caused by the accumulation of amyloid\u2010beta (A<jats:italic>\u03b2<\/jats:italic>) proteins and neurofibrillary tangles in the brain. There have been recent advancements in antiamyloid therapy for AD. This narrative review explores the recent advancements and challenges in antiamyloid therapy. In addition, a summary of evidence from antiamyloid therapy trials is presented with a focus on lecanemab. Lecanemab is the most recently approved monoclonal antibody that targets A<jats:italic>\u03b2<\/jats:italic> protofibrils for the treatment of patients with early AD and mild cognitive impairment (MCI). Lecanemab was the first drug shown to slow cognitive decline in patients with MCI or early onset AD dementia when administered as an infusion once every two weeks. In the Clarity AD trial, lecanemab was associated with infusion\u2010site reactions (26.4%) and amyloid\u2010related imaging abnormalities (12.6%). The clinical relevance and long\u2010term side effects of lecanemab require further longitudinal observation. However, several challenges must be addressed before the drug can be routinely used in clinical practice. The drug\u2019s route of administration, need for imaging and genetic testing, affordability, accessibility, infrastructure, and potential for serious side effects are some of these challenges. Lecanemab\u2019s approval has fueled interest in the potential of other antiamyloid therapies, such as donanemab. Future research must focus on developing strategies to prevent AD; identify easy\u2010to\u2010use validated plasma\u2010based assays; and discover newer user\u2010friendly, and cost\u2010effective drugs that target multiple pathways in AD pathology.<\/jats:p>","DOI":"10.1155\/2024\/2052142","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T04:35:03Z","timestamp":1721709303000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Advancements and Challenges in Antiamyloid Therapy for Alzheimer\u2019s Disease: A Comprehensive Review"],"prefix":"10.1155","volume":"2024","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4990-4783","authenticated-orcid":false,"given":"Semira Abdi","family":"Beshir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6314-2485","authenticated-orcid":false,"given":"Nadia","family":"Hussain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2030-0962","authenticated-orcid":false,"given":"Vineetha Bharathan","family":"Menon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4411-5577","authenticated-orcid":false,"given":"Amal H. I.","family":"Al Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1752-3171","authenticated-orcid":false,"given":"Rahaf Adnan Kh.","family":"Al Zeer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4143-7810","authenticated-orcid":false,"given":"Asim Ahmed","family":"Elnour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"e_1_2_7_1_2","unstructured":"World Health Organization (WHO) Dementia. Key facts https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/dementia."},{"key":"e_1_2_7_2_2","doi-asserted-by":"crossref","unstructured":"Alzheimer\u2019s Association 2024 Alzheimer\u2019s disease facts and figures. 20(5).Special report mapping a better future for dementia care navigation https:\/\/www.alz.org\/media\/Documents\/2024-Facts-and-Figures-Report.pdf.","DOI":"10.1002\/alz.13809"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S200490"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1590\/0001-3765201520140716"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1566067"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.3892\/br.2016.630"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2536"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/60.8.759"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0006-291x(84)80190-4"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00308809"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-022-00545-9"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.7046051"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.286.5440.735"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13365-019-00736-z"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199603213341202"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32205-4"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-021-03986-5"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2022.05.017"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnen\/62.12.1287"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.3390\/ph13110394"},{"key":"e_1_2_7_21_2","doi-asserted-by":"crossref","DOI":"10.1007\/s13139-024-00848-3","volume-title":"Anti-Amyloid Antibody Therapies for Alzheimer\u2019s Disease","author":"Park K. W.","year":"2024"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312889"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1304839"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1705971"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01308-6"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2875"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.3233\/JAD-230164"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14020411"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2023.1102809"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12987-022-00398-w"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.3389\/fddev.2023.1227816"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1021\/mp400348n"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241914499"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201019"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01484-7"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2023.13239"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2014.01.002"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12385"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1471-4159.2007.04759.x"},{"key":"e_1_2_7_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2009.08.007"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-016-0181-2"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.7230"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-021-00813-8"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-01124-2"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2212948"},{"key":"e_1_2_7_46_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-023-01331-1"},{"key":"e_1_2_7_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-022-00350-y"},{"key":"e_1_2_7_48_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12748"},{"key":"e_1_2_7_49_2","doi-asserted-by":"publisher","DOI":"10.1177\/10600280231218253"},{"key":"e_1_2_7_50_2","unstructured":"Eisai Co. EISAI Presents New LEQEMBI\u00ae (lecanemab-irmb) Investigational Subcutaneous Formulation Interim Study Results and Clinical Improvement Data in Earlier Stages of Early Alzheimer\u2019s Disease From Additional Analyses of Clarity AD at The Clinical Trials on Alzhe 2023 December 2023 https:\/\/investors.biogen.com\/news-releases\/news-release-details\/eisai-presents-new-leqembir-lecanemab-irmb-investigational%250A%250A."},{"key":"e_1_2_7_51_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207770"},{"key":"e_1_2_7_52_2","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2020.88481"},{"key":"e_1_2_7_53_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.85"},{"key":"e_1_2_7_54_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.12134"},{"key":"e_1_2_7_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01382-x"},{"key":"e_1_2_7_56_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12756"},{"key":"e_1_2_7_57_2","doi-asserted-by":"publisher","DOI":"10.1590\/0004-282X-ANP-2022-S117"},{"key":"e_1_2_7_58_2","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2019.06.180328"},{"key":"e_1_2_7_59_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.46"},{"key":"e_1_2_7_60_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2023.30"},{"key":"e_1_2_7_61_2","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13759"},{"key":"e_1_2_7_62_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2023.100467"},{"key":"e_1_2_7_63_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2023.1749"},{"key":"e_1_2_7_64_2","unstructured":"CMS.gov 2023 December 2023 https:\/\/www.cms.gov\/newsroom\/press-releases\/statement-broader-medicare-coverage-leqembi-available-following-fda-traditional-approval."},{"key":"e_1_2_7_65_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.25"},{"key":"e_1_2_7_66_2","volume-title":"Our health systems aren\u2019t ready for the full approval of lecanemab \u2014 screening, administration, and eligibility concerns remain","author":"Yang M.","year":"2023"},{"key":"e_1_2_7_67_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.34"},{"key":"e_1_2_7_68_2","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2022.862369"},{"key":"e_1_2_7_69_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2022.21"},{"key":"e_1_2_7_70_2","doi-asserted-by":"publisher","DOI":"10.14283\/jpad.2020.24"},{"key":"e_1_2_7_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/bs.irn.2020.03.022"},{"key":"e_1_2_7_72_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2100708"},{"key":"e_1_2_7_73_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2022.2793"},{"key":"e_1_2_7_74_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43933-5"},{"key":"e_1_2_7_75_2","doi-asserted-by":"publisher","DOI":"10.2174\/1568026620666200422105156"},{"key":"e_1_2_7_76_2","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15015"},{"key":"e_1_2_7_77_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-022-00292-3"},{"key":"e_1_2_7_78_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173554"},{"key":"e_1_2_7_79_2","doi-asserted-by":"publisher","DOI":"10.1684\/pnv.2022.1042"},{"key":"e_1_2_7_80_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30489-0"},{"key":"e_1_2_7_81_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-023-00596-6"},{"key":"e_1_2_7_82_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-018-0013-z"},{"key":"e_1_2_7_83_2","doi-asserted-by":"publisher","DOI":"10.1159\/000534400"},{"key":"e_1_2_7_84_2","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1257700"},{"key":"e_1_2_7_85_2","doi-asserted-by":"publisher","DOI":"10.1002\/alz.046751"},{"key":"e_1_2_7_86_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-023-01169-x"},{"key":"e_1_2_7_87_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainres.2020.147264"},{"key":"e_1_2_7_88_2","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2021.630055"},{"key":"e_1_2_7_89_2","doi-asserted-by":"publisher","DOI":"10.1080\/17425247.2023.2286371"},{"key":"e_1_2_7_90_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijbiomac.2022.03.203"},{"key":"e_1_2_7_91_2","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2019.367"},{"key":"e_1_2_7_92_2","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddaa179"},{"key":"e_1_2_7_93_2","doi-asserted-by":"publisher","DOI":"10.1089\/humc.2017.231"},{"key":"e_1_2_7_94_2","doi-asserted-by":"publisher","DOI":"10.1111\/cns.12312"},{"key":"e_1_2_7_95_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-017-0307-1"},{"key":"e_1_2_7_96_2","doi-asserted-by":"publisher","DOI":"10.4103\/1673-5374.369096"},{"key":"e_1_2_7_97_2","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/7834421"},{"key":"e_1_2_7_98_2","doi-asserted-by":"publisher","DOI":"10.4252\/wjsc.v12.i8.787"},{"key":"e_1_2_7_99_2","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202006357"},{"key":"e_1_2_7_100_2","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14040823"},{"key":"e_1_2_7_101_2","unstructured":"Alzforum Therapeutics\/leqembi June 2023 https:\/\/www.alzforum.org\/therapeutics\/leqembi."}],"container-title":["International Journal of Alzheimer\u2019s Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/2024\/2052142","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T04:35:13Z","timestamp":1721709313000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/2024\/2052142"}},"subtitle":[],"editor":[{"given":"John","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":101,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1155\/2024\/2052142"],"URL":"https:\/\/doi.org\/10.1155\/2024\/2052142","archive":["Portico"],"relation":{},"ISSN":["2090-8024","2090-0252"],"issn-type":[{"value":"2090-8024","type":"print"},{"value":"2090-0252","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"2024-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-19","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"2052142"}}